Vitro

ZRG Global Talent Advisory Firm Establishes Presence in Mexico City

Retrieved on: 
Monday, November 27, 2023
Speciality chemicals, Consultant, Green building council, ZRG, State, Medical device, Kimberly-Clark, Korn Ferry, Vitro, Walking, Consumer, Talk, Sport, CITY, Training and development, Professional services, Acceleration, Automotive industry

MEXICO CITY and ROCHELLE PARK, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- ZRG , a New Jersey-based global talent advisory firm, has established a new office in Mexico City, located in the U.S. Green Building Council LEED Platinum-certified Torre Virreyes Building in the Lomas de Chapultepec.

Key Points: 
  • MEXICO CITY and ROCHELLE PARK, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- ZRG , a New Jersey-based global talent advisory firm, has established a new office in Mexico City, located in the U.S. Green Building Council LEED Platinum-certified Torre Virreyes Building in the Lomas de Chapultepec.
  • “Mexico is the biggest trading partner of the United States,” said Nate Frank, President ZRG Executive Search Division.
  • ZRG brings to Mexico an expanded service offering including Organizational Culture Assessment, Consulting and transformation through its Walking the Talk division.
  • He is also the co-founder of The Morphing Group LLC, a business transformation advisory firm.

Guerbet to Spotlight Diagnostic Solutions at the 2023 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting

Retrieved on: 
Monday, November 27, 2023
University of Colorado Denver, South Hall (UC Berkeley), Relaxation, Glomerular filtration rate, Fractional dose vaccination, Blood, University, Guerbet, Doctor of Philosophy, Risk, MRI, AI, Radiology, CST, Medical imaging, MD, Vitro

PRINCETON, N.J., Nov. 27, 2023 /PRNewswire/ -- Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today its schedule of activities at the 2023 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting from November 26-30 in Chicago, IL. In addition to the Guerbet exhibit (booth #1711), the company will be presenting safety data in an abstract titled "Safety of gadopiclenol for magnetic resonance imaging (MRI): a pooled analysis of eight studies." The session number W3-STCE1, will be presented as a scientific session on Wednesday, November 29 at 10:00-10:30 a.m. CST.

Key Points: 
  • Jeffrey H Maki, MD, PhD, Professor of Radiology and Director of MRI at the University of Colorado in Denver will be presenting "Relaxation properties of GBCAs In Vitro, in human blood – their unique behavior might surprise you" at 1:00 p.m. CST on Monday, November 27th.
  • This presentation, which will take place in the RSNA Innovation Theater Exhibitor Pavillion in the South Hall, is based on a study done to measure T1 and T2 relaxivity In Vitro, in human blood.
  • In addition to showcasing diagnostic and interventional solutions, Guerbet will also feature its digital and AI software-based products that help to close the loop with the smart connectivity between monitoring and reporting.
  • Products that will be featured include:
    Contrast & Care®, an injection data management solution that enables imaging centers to collect, archive, examine, and share injection data, including data on contrast products, adverse events, injector activity, information on estimated glomerular filtration rate, and other risk factors before a clinical exam
    Optistar™ Elite, a dual head contrast delivery system with an ultrasonic motor that makes it non-magnetic, built for long lasting performance and now has the new Fractional Dosing capabilities

Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
FDA, Research, PKU, Patent, AbbVie, PAL, International Conference on Nuclear Disarmament, Oslo, 2008, Homocystinuria, Treatment, University, Conference, Progress, Phenylketonuria, Partnership, Head, United States patent law, Methionine, Lead, Pittsburgh, Investment, Inflammatory bowel disease, Nature Metabolism, Nursing, Pharmaceutical industry, Cryptocurrency, Vitro

CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Key Points: 
  • Publication of Synpheny-1 Phase 2 study results for the PKU program in the journal Nature Metabolism.
  • Presentation of Synpheny-1 Phase 2 study results by lead investigator Dr. Jerry Vockley of the University of Pittsburgh at the 37th E.S.PKU Conference 2023.
  • Revenue for the three months ended September 30, 2023 was $0.4 million compared to $0.7 million for the corresponding period in 2022.
  • General and administrative expenses were $3.4 million for the three months ended September 30, 2023, compared to $4.4 million for the corresponding period in 2022.

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers

Retrieved on: 
Thursday, November 9, 2023
Colon, Medication, Weight gain, Research, Argyreia nervosa, CB2, National Center for Advancing Translational Sciences, Senior, Quality of life, Trinity College, Life expectancy, Trinity College Dublin, Cancer, Pain, Patient, Associate, Atrophy, Appetite, Pharmaceutical industry, Medical device, Vitro

The research article, titled “ Cancer-Cachexia-Induced Human Skeletal Muscle Myotube Degeneration is Prevented via Cannabinoid Receptor 2 Agonism in Vitro ,” highlights the promising protective properties of the Company’s clinical asset, ART27.13, in helping prevent muscle degeneration caused by cancer.

Key Points: 
  • The research article, titled “ Cancer-Cachexia-Induced Human Skeletal Muscle Myotube Degeneration is Prevented via Cannabinoid Receptor 2 Agonism in Vitro ,” highlights the promising protective properties of the Company’s clinical asset, ART27.13, in helping prevent muscle degeneration caused by cancer.
  • Senior author Dr. Richard K. Porter, Associate Professor at Trinity College Dublin, Ireland, stated, “This groundbreaking research demonstrated ART27.13’s ability to protect against muscle degeneration associated with colon and lung cancers.
  • The purpose of this new research was to establish whether ART27.13 may additionally impact muscle degradation, a common debilitating effect of cancer and its treatment.
  • Not only did the research show that ART27.13 protects against muscle wasting in the in vitro model, but also shows that the activity was mediated by the CB2 receptor.

Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Screening

Retrieved on: 
Tuesday, November 7, 2023
Data Management, Biotechnology, Alternative Medicine, Technology, FDA, Health, Pharmaceutical, Oncology, Research, Science, Clinical Trials, Carboplatin, AACR, HCI, WES, Organoid, 2D, RNA, Cisplatin, Crown Bioscience International, Timeline, Doctor of Philosophy, KRAS, Senior, Sequence, Paclitaxel, RNA-Seq, NGS, Drug discovery, PDX, ANE, CTG, AR, Automation, Medical imaging, Vitro

This large-scale organoid panel screening platform promises robust, reproducible, and clinically relevant output at record speed, accelerating preclinical oncology drug discovery by empowering researchers and reshaping the landscape of cancer treatment development.

Key Points: 
  • This large-scale organoid panel screening platform promises robust, reproducible, and clinically relevant output at record speed, accelerating preclinical oncology drug discovery by empowering researchers and reshaping the landscape of cancer treatment development.
  • Screening of a large panel of patient-derived organoids is enabled using Crown Bioscience’s unique assay-ready (AR) organoid technology.
  • OrganoidXplore transcends traditional 2D cell culture systems in terms of patient relevance, heralding a significant leap in preclinical drug screening.
  • The Full Panel currently comprises 50 organoid models covering seven cancer indications, which are also available as companion Patient-Derived Xenografts (PDX).

Edgewise to Present Data on EDG-7500 at the American Heart Association’s Scientific Sessions 2023

Retrieved on: 
Wednesday, November 1, 2023
Health, Genetics, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Heart failure, Intrinsic and extrinsic properties, Edgewise, Hypertrophic cardiomyopathy, Poster, American Heart, HCM, Therapy, AHA, Rapid Fire, Medical device, Vitro

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present the results of nonclinical studies of EDG-7500 at the American Heart Association’s (AHA) Scientific Sessions 2023 being held in Philadelphia from November 11 - 13.

Key Points: 
  • Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present the results of nonclinical studies of EDG-7500 at the American Heart Association’s (AHA) Scientific Sessions 2023 being held in Philadelphia from November 11 - 13.
  • EDG-7500 is a first-in-class oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction.
  • Details of the Rapid Fire Oral Presentation:
    Title: EDG-7500, a Novel Cardiac Sarcomere Regulator That Preserves Intrinsic Myosin-Motor Function, Improves Cardiac Function and Reserve in a Minipig Model of Hypertrophic Cardiomyopathy
    Session: The Pharmacologic Management of Heart Failure: Beyond Guidelines and Paradigms
    Details of the Scientific Poster Presentation:
    Title: Cardiac Effects of EDG-7500, a Novel Cardiac Sarcomere Regulator: In Vitro and In Vivo Evidence for Slowing Isovolumic Contraction and Improved Ventricular Compliance (Board #2163)
    The AHA Scientific Sessions’ program is available here .
  • The Edgewise presentation and poster will be available on the Edgewise website when they are presented.

Guerbet to Spotlight Diagnostic and Interventional Solutions at the 2023 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
MRI, CST, University of Colorado Denver, Radiology, South Hall (UC Berkeley), Doctor of Philosophy, Glomerular filtration rate, Guerbet, Relaxation, Risk, Fractional dose vaccination, University, Blood, AI, Medical imaging, MD, Vitro

PRINCETON, N.J., Nov. 2, 2023 /PRNewswire/ -- Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today its schedule of activities at the 2023 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting from November 26-30 in Chicago, IL. In addition to the Guerbet exhibit (booth #1711), the company will be presenting safety data in an abstract titled "Safety of gadopiclenol for magnetic resonance imaging (MRI): a pooled analysis of eight studies." The session number W3-STCE1, will be presented as a scientific session on Wednesday, November 29 at 10:00-10:30 a.m. CST.

Key Points: 
  • Jeffrey H Maki, MD, PhD, Professor of Radiology and Director of MRI at the University of Colorado in Denver will be presenting "Relaxation properties of GBCAs In Vitro, in human blood – their unique behavior might surprise you" at 1:00 p.m. CST on Monday, November 27th.
  • This presentation, which will take place in the RSNA Innovation Theater Exhibitor Pavillion in the South Hall, is based on a study done to measure T1 and T2 relaxivity In Vitro, in human blood.
  • In addition to showcasing diagnostic and interventional solutions, Guerbet will also feature its digital and AI software-based products that help to close the loop with the smart connectivity between monitoring and reporting.
  • Products that will be featured include:
    Contrast & Care®, an injection data management solution that enables imaging centers to collect, archive, examine, and share injection data, including data on contrast products, adverse events, injector activity, information on estimated glomerular filtration rate, and other risk factors before a clinical exam
    Optistar™ Elite, a dual head contrast delivery system with an ultrasonic motor that makes it non-magnetic, built for long lasting performance and now has the new Fractional Dosing capabilities

Greenberg Traurig Mexico Represented BBVA, Banorte and Scotiabank in Arranging a USD $490 Million Five-year Loan for Mexican Glass Manufacturer Vitro

Retrieved on: 
Wednesday, November 1, 2023
Scotiabank, BBVA, Glass, Vitro, MEXICO, Drug, Bank

MEXICO CITY, Oct. 31, 2023 /PRNewswire-PRWeb/ -- Attorneys from global law firm Greenberg Traurig's Mexico City office represented BBVA, Banorte and Scotiabank banks in setting up a USD $490 million five-year "club deal" loan, for Vitro, a leading glass manufacturing company in Mexico.

Key Points: 
  • Attorneys from global law firm Greenberg Traurig's Mexico City office represented BBVA, Banorte and Scotiabank banks in setting up a USD $490 million five-year "club deal" loan, for Vitro, a leading glass manufacturing company in Mexico.
  • MEXICO CITY, Oct. 31, 2023 /PRNewswire-PRWeb/ -- Attorneys from global law firm Greenberg Traurig 's Mexico City office represented BBVA, Banorte and Scotiabank banks in setting up a USD $490 million five-year "club deal" loan, for Vitro, a leading glass manufacturing company in Mexico.
  • Vitro will use the proceeds to prepay all of its short-term debt and a portion of its long-term debt.
  • This transaction allows Vitro to extend the average maturity of its debt while keeping its short-term credit lines freed up.

Venture Metals+ Names John T Shaddox as Chief Executive Officer

Retrieved on: 
Wednesday, September 13, 2023
Marketing, Culture, Ardagh Group, History, Ardagh, Vitro, Dallas Police Department, Dallas, Growth, O-I Glass, Entrepreneurship, SVP, Metal, Management

NEW YORK, Sept. 13, 2023 /PRNewswire/ -- Venture Metals+ ("Venture Metals" or the "Company"), a leading provider of high-touch recycling solutions to the industrials, manufacturing, energy and metals sectors, announced today that it has appointed John T Shaddox as Chief Executive Officer.

Key Points: 
  • NEW YORK, Sept. 13, 2023 /PRNewswire/ -- Venture Metals+ ("Venture Metals" or the "Company"), a leading provider of high-touch recycling solutions to the industrials, manufacturing, energy and metals sectors, announced today that it has appointed John T Shaddox as Chief Executive Officer.
  • Mr. Shaddox brings nearly three decades of general management experience to Venture Metals, comprising both commercial and operational roles.
  • Venture Metals' Co-Founders and Directors Mike Uhrick and Mark Chazanow added, "We are thrilled to welcome John T to the team.
  • "We are delighted to announce John T's appointment as Chief Executive Officer of Venture Metals," stated Chris Whalen and Adi Pekmezovic, Venture Metals Directors and Co-Founders of Mill Rock Capital.

TCI Dominates 2023 Asia-Pacific Stevie® Awards with Three Prestigious Innovation Wins

Retrieved on: 
Wednesday, September 6, 2023
ODM, Education, Oscar, TCI, Biodiversity park, Hyderabad, Stevie Awards, Oct, Biodiversity, CDMO, People's Choice Awards, Health, 3rd Indonesian Choice Awards, Safety, Maintenance (technical), Science, Vitro

Established in 2002, the Stevie Award is the highest honor in the American business community and the Oscar of the business world.

Key Points: 
  • Established in 2002, the Stevie Award is the highest honor in the American business community and the Oscar of the business world.
  • Innovation, quality, safety, and speed have been the most crucial standards of the one-stop service TCI provides customers.
  • TCI provides low-carbon and carbon-neutralized products and applies recyclable and recycled material in the packages; several products are incorporated with biodegradable material.
  • The different nationalities, education, and professional backgrounds offer different perspectives, allowing TCI to continue leading the industry in innovation.